Peter J. Van Veldhuizen, MD

home / authors / peter-j-van-veldhuizen-md

Articles

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

Gina Mauro;Toni K. Choueiri, MD;Peter J. Van Veldhuizen, MD

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

Dr. Van Veldhuizen Discusses Combination Therapy in RCC

Peter J. Van Veldhuizen, MD

September 19th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

Peter J. Van Veldhuizen, MD

September 7th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Dr. Van Veldhuizen Reflects on the CARMENA Trial in RCC

Peter J. Van Veldhuizen, MD

August 20th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

Peter J. Van Veldhuizen, MD

July 13th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.